These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 21104392)

  • 1. Feeding disorders and obesity.
    Cervino C; Vicennati V; Pasquali R; Pagotto U
    Curr Top Behav Neurosci; 2009; 1():373-85. PubMed ID: 21104392
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Endocannabinoid system and energy metabolism: physiology and pathophysiology].
    Pagotto U; Vicennati V; Pasquali R
    G Ital Cardiol (Rome); 2008 Apr; 9(4 Suppl 1):74S-82S. PubMed ID: 18773754
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The endocannabinoid system and energy metabolism.
    Bellocchio L; Cervino C; Pasquali R; Pagotto U
    J Neuroendocrinol; 2008 Jun; 20(6):850-7. PubMed ID: 18601709
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The endocannabinoid system: a new target for the regulation of energy balance and metabolism.
    Després JP
    Crit Pathw Cardiol; 2007 Jun; 6(2):46-50. PubMed ID: 17667864
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Endocannabinoid control of food intake and energy balance.
    Di Marzo V; Matias I
    Nat Neurosci; 2005 May; 8(5):585-9. PubMed ID: 15856067
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The emerging role of the endocannabinoid system in endocrine regulation and energy balance.
    Pagotto U; Marsicano G; Cota D; Lutz B; Pasquali R
    Endocr Rev; 2006 Feb; 27(1):73-100. PubMed ID: 16306385
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cannabinoid-1 receptor inverse agonists: current understanding of mechanism of action and unanswered questions.
    Fong TM; Heymsfield SB
    Int J Obes (Lond); 2009 Sep; 33(9):947-55. PubMed ID: 19597516
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of the endocannabinoid system in energy balance regulation and obesity.
    Cota D
    Front Horm Res; 2008; 36():135-145. PubMed ID: 18230900
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Rimonabant (Acomplia), specific inhibitor of the endocannabinoid system].
    Ducobu J; Sternon J
    J Pharm Belg; 2005; 60(3):89-91. PubMed ID: 16252510
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Pharmacology of cannabinoid receptors].
    Le Fur G; Rinaldi-Carmona M; Barth F; Alexander J
    Bull Acad Natl Med; 2007; 191(4-5):933-8; discussion 938-40. PubMed ID: 18225447
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The endocannabinoid system as a novel approach for managing obesity.
    Lillo JL
    J Am Osteopath Assoc; 2007 Apr; 107(4 Suppl 2):S12-20. PubMed ID: 17784530
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The endocannabinoid system as a target for the treatment of visceral obesity and metabolic syndrome.
    Kyrou I; Valsamakis G; Tsigos C
    Ann N Y Acad Sci; 2006 Nov; 1083():270-305. PubMed ID: 17148745
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Endocannabinoid system and cardiometabolic risk.
    Saavedra LE
    Clin Pharmacol Ther; 2007 Nov; 82(5):591-4. PubMed ID: 17898706
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The unfolding cannabinoid story on energy homeostasis: central or peripheral site of action?
    Horvath TL
    Int J Obes (Lond); 2006 Apr; 30 Suppl 1():S30-2. PubMed ID: 16570102
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of CB1 antagonist on the control of metabolic functions in obese type 2 diabetic patients.
    Lafontan M; Piazza PV; Girard J
    Diabetes Metab; 2007 Apr; 33(2):85-95. PubMed ID: 17418607
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cannabinoid receptors as therapeutic targets for obesity and metabolic diseases.
    Bellocchio L; Mancini G; Vicennati V; Pasquali R; Pagotto U
    Curr Opin Pharmacol; 2006 Dec; 6(6):586-91. PubMed ID: 17027338
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Food intake-independent effects of CB1 antagonism on glucose and lipid metabolism.
    Cota D; Sandoval DA; Olivieri M; Prodi E; D'Alessio DA; Woods SC; Seeley RJ; Obici S
    Obesity (Silver Spring); 2009 Aug; 17(8):1641-5. PubMed ID: 19325539
    [TBL] [Abstract][Full Text] [Related]  

  • 18. End of the line for cannabinoid receptor 1 as an anti-obesity target?
    Jones D
    Nat Rev Drug Discov; 2008 Dec; 7(12):961-2. PubMed ID: 19043439
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The endocannabinoid system and the treatment of obesity.
    Pagotto U; Vicennati V; Pasquali R
    Ann Med; 2005; 37(4):270-5. PubMed ID: 16019725
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of the endocannabinoid noladin ether on body weight, food consumption, locomotor activity, and cognitive index in mice.
    Avraham Y; Menachem AB; Okun A; Zlotarav O; Abel N; Mechoulam R; Berry EM
    Brain Res Bull; 2005 Mar; 65(2):117-23. PubMed ID: 15763177
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.